$NSPX has a legit drug, where it goes only longs will find out. I’ve posted an email thread from a Brazilian University Published researcher that agreed that the commercial supply was a big problem. This company needs funding, getting current, RS was a means to that.
Phyton BioTech resubmitted, Sept. 30th, 2019, an updated Oral Hearing Patent request for Synthesizing "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE".
Once they get this patent approved they will solve the Commercial Supply issues. Its been ongoing Since 2016.... Coincidentally around the same time $NSPX started getting quite. https://portal.uspto.gov/pair/PublicPair
Application Number - 15/100780
Think about it...
Started getting current in April 2019
June 17th, 2019 Updated Phase II report Published, no hype/PR.. Just Published Medically and Scientifically. https://www.mdpi.com/2072-6694/11/6/833
September 13th, 2019 They become fully reported..
October 1st, 2019 minimal RS..
October 3, 2019 Commercial Supply issue on verge of being resolved with the excepted review of the Patent submission.
During this entire time the only money the company has spent was on Getting SEC updated and OTC Current.
There are no fake/misleading/hype/crappy PR's promising anything.